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other treatment related effects such as nausea. The present study
was designed to estimate the utility decrement associated with
increasing severities of anaemia. METHODS: Existing trial data
was summarized in order to deﬁne health states related to the
following haemoglobin levels: 7.0–8.0; 8.0–9.0; 9.0–10.0;
10.0–10.5; 10.5–11.0; 11.0–12.0; and 12+g/dL. These health
states were based on the FACT-An fatigue related items and were
reviewed by clinicians and two quality of life experts. Forty inter-
views with the general public (recruited through advertisements)
were conducted where participants were asked to rate the health
states using a visual analogue scale (VAS) and standard gamble
(SG). RESULTS: Mean (+95% CI) utility values were calculated
for each health state anchored against death. The VAS scores
ranged from 19.3 ± 3.9 for 7–8g/dL Hb to 53.8 3 ± 6.7 for 12+
g/dL Hb. The standard gamble derived utility values showed a
broadly linear change from 0.59 ± 0.10 for 7–8g/dL Hb to 0.75
± 0.09 for 12+g/dL Hb. CONCLUSIONS: The health state
utility scores show a linear decrement in line with worsening
anaemia. These data underline the importance of cancer related
fatigue for the general public.
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OBJECTIVES: Anaemia is a common complication in cancer
patients undergoing chemotherapy. Although quality-of-life
(QoL) in CRA has been studied, utility values related to anaemia
severity are lacking. The UK National Institute for Clinical
Excellence (NICE) requests cost-utility analysis based on quality-
adjusted life-years (QALY’s) incorporating utilities elicited using
public preferences. The objective was to use an appropriate
method to estimate the impact of CRA, from a societal perspec-
tive. METHODS: A time-trade-off (TTO) questionnaire was
designed and administered to a sample of laypeople: CRA health
states were deﬁned and described, based on the EuroQoL (EQ-
5D) instrument, and the Functional Assessment of Cancer
Therapy—Anaemia (FACT-An) instrument, and validated by
clinical experts and cancer patients who had experienced
anaemia. These descriptions were valued using the TTO elicita-
tion method. Written informed consent was obtained and trained
interviewers conducted surveys during February–March, 2004.
RESULTS: In total, 110 respondents were interviewed; ﬁnal
analyses were performed on 106 respondents’ data. Resultant
utility scores were converted to ratios, reﬂecting the baseline of
“cancer and chemotherapy, with no anaemia”. Mean utility
scores [SE] are 0.856 [0.014] for the no-anaemia state, and 0.781
[0.016], 0.615 [0.020] and 0.481 [0.020] for mild, moderate and
severe anaemia states, respectively (Ratios of 1.00, 0.91, 0.72,
and 0.56, respectively). CONCLUSIONS: This study strongly
highlights a societal view that severity of cancer-related anaemia
will signiﬁcantly affect patient utility. For example, a change
from no-anaemia to severe anaemia is predicted to approxi-
mately halve utility, independent of other factors. TTO 
appears to be a valid, and sufﬁciently sensitive method to high-
light this effect. The ratios of relative effect are applicable to a
range of “baseline” cancer utilities as multiplicative factors 
to estimate impact of anaemia within this broader context. 
These results could be incorporated within appraisals of thera-
pies for CRA, and satisfy certain health technology assessment
criteria.
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OBJECTIVES: Blood transfusion and rh-EPO are alternative
treatment options for CRA. Potential beneﬁts of rh-EPO treat-
ment include improved health outcomes, but also more conve-
nient administration. The objective was to elicit public
preference scores associated with differences in these aspects of
treatment, and subsequently use these “valued preferences”
within a willingness-to-pay (WTP) analysis of cost-effectiveness
of NeoRecormon (rh-EPO beta) versus transfusion. METHODS:
A discrete choice experiment (DCE) was designed and adminis-
tered to a sample of laypeople. Important aspects of treatment
were deﬁned through a literature review, plus input from expert
clinician and patient interviews. An out-of-pocket cost attribute
was included in order to estimate WTP values. Lay people were
surveyed during February–March, 2004. A random effects probit
model was used to analyse the data. WTP values for aspects of
treatment were obtained by estimating the marginal rate of sub-
stitution between treatment attributes and the cost coefﬁcient.
Mean values of a unit improvement in each attribute level were
used in an economic welfare analysis of the value of shifting from
transfusion to NeoRecormon. RESULTS: A total of 110 respon-
dents completed the DCE questionnaire. Final analyses were per-
formed on 1086 observations, and showed high consistency,
reliability, and face-validity. The following preferences were sig-
niﬁcant predictors of choice (p < 0.001): Effectiveness: Higher
level of relief from fatigue; Administration of treatment: Lower
duration, subcutaneous/intravenous versus cannula injection,
and GP versus hospital location; Safety: Lower risk of infec-
tion/allergic reaction; and Lower cost. Attribute levels were
valued higher for NeoRecormon than for transfusion. This is
reﬂected in an incremental welfare value of GBP368[95% CI:
GBP318-GBP419]. CONCLUSIONS: This study shows that the
public value the favourable attributes of treatment with rh-EPO,
and indicates a likely patient preference for treatment with Neo-
Recormon over blood transfusion. This type of WTP analysis
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OBJECTIVES: Anastrozole provides a treatment alternative for
patients with EBC who cannot tolerate tamoxifen or in whom
the drug is contraindicated. This study aimed to examine the
value patients place on the ability of a treatment to decrease the
